everhopeful April 18, 2019, 12:42pm #1

Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.

4 Likes

Powered by Discourse, best viewed with JavaScript enabled

Schizophrenia.com

Iti-007 / lumateperone